Login Register Cart 0
Generic placeholder image

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

3D-QSAR CoMFA Studies on Benzenesulfonamides with Benzimidazole Moieties as Inhibitors of Carbonic Anhydrases XII as Antitumor Agents

Author(s): Shalini Singh*

Volume 15, Issue 1, 2019

Page: [69 - 77] Pages: 9

DOI: 10.2174/1573408015666190402100338

Abstract

Introduction: In recent times, a new very significant research area has developed and obtained the potential use of Carbonic Anhydrase inhibitors as Antitumor agents.

Methods: A series of sulfonamides and Benzenesulfonamides with benzimidazole moieties to inhibit CSXII was considered in this study.

Results and Conclusion: The best model was obtained with a predictive r2 value of 0.678 and cross validated coefficient q2 value as 0.529 in tripos CoMFA region. The paper shows that the electrostatic and steric effects are important features in Carbonic Anhydrase XII inhibition for the investigated compounds. The effort has been undertaken to search for the structural aspects of bioactive molecules.

Keywords: 3D-QSAR CoMFA, carbonic anhydrase inhibitors, human membrane associated isoform (CAXII), sulfonamides, metalloenzyme, CoMFA region.

« Previous
Graphical Abstract

[1]
Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7, 168-181.
[2]
Mincione, F.; Menabuoni, L.; Supuran, C.T. Clinical applicationsof the Carbonic anhydrase inhibitors in ophthalmology. In: Supuran C, Scozzafava A, Conway J, Eds. Carbonic anhydrase, its inhibitors and activators; Boca Raton (FL): CRC Press, 2004; pp. 243-254.
[3]
Supuran, C.T.; Scozzafava, A.; Conway, J., Eds.; Carbonicanhydrase-its inhibitors and activators; Boca Raton, USA: CRC Press, 2004, pp. 1-363.
[4]
Clare, B.W.; Supuran, C.T. Boca Raton, FI; USA: CRC Press, 2004.
[5]
Jiang, Y-R.; Chen, Y-L.; Yang, Y-Y.; Liu, Q. Quantitative structure-activity relationship of 2-alkyl-4-(biphenylylmethoxy) pyridine 5derivatives with AT1 receptor antagonistic activity. J. Cent. South Univ., 2012, 19(5), 1212-1218.
[6]
Nordfors, K.; Haapasalo, J.; Korja, M. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Can, 2010, 10, 148-158.
[7]
Chien, M.H.; Ying, T.H.; Hsieh, Y.H. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol., 2012, 48, 417-423.
[8]
Zubriene, A.; Edita, C.; Joana, G.; Migle, K.; Sigitas, T.; Daumantas, M. Benzene sulphonamides with benzimidazole moieties as inhibitors of carbonic anhydrase I, II, VII, XII and XIII. J. Enz Inhib. Med. Chem., 2014, 29(1), 124-131.
[9]
Garaj, V.; Puccetti, L. Giuseppe.; Fasolis, Winum, J.Y. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg. Med. Chem. Lett., 2005, 15, 3102-3108.
[10]
Supuran, C.T.; Innocenti, A.; Mastrolorenzo, A.; Scozzafava, A. Antiviral sulfonamide derivatives. Mini Rev. Med. Chem., 2004, 4, 189-200.
[11]
Carta, F.; Scozzafava, A.; Supuran, C.T. Sulfonamides: A patent review (2008-2012). Expert Opin. Ther. Pat., 2012, 22, 747-758.
[12]
Singh, S. A Comparative Molecular Field (CoMFA) Studies on Carbonic Anhydrase Inhibitor hCA IX—Tumor-Associated (Hypoxia). Lett. Drug Des. Discov., 2011, 8, 877-883.
[13]
Singh, S. In silico molecular modeling of Carbonic anhydrase inhibitors: Inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides. Bioorg. Med. Chem. Lett., 2015, 25, 133-141.
[14]
Singh, S.; Supuran, C.T. 3D-QSAR CoMFA studies on sulfonamide inhibitors of the Rv3588c β-carbonic anhydrase from Mycobacterium tuberculosis and design of not yet synthesized new molecules. J. Enz. Inhib. Med. Chem., 2014.
[15]
Geladi, P. Notes on the history and nature of partial least squares (PLS) modeling. J. Chem., 1988, 2, 231-246.
[16]
Cramer, R.D. III.; Bunce, J.D.; Patterson, D.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR. Quant. Struct. Act. Relat., 1988, 7, 18-25.
[17]
Thaimattam, R. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. Bioorg. Med. Chem., 2004, 1215.

Rights & Permissions Print Cite
Article Metrics
45
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy